Peter Kuan-How Lin Purchases 26,667 Shares of Apollomics (NASDAQ:APLM) Stock

Apollomics Inc. (NASDAQ:APLM) CFO Peter Kuan-How Lin bought 26,667 shares of Apollomics stock in a transaction that occurred on Friday, August 14th. The shares were acquired at an average cost of $15.00 per share, with a total value of $400,005.00. Following the acquisition, the chief financial officer owned 48,979 shares of the company’s stock, valued at $734,685. The trade was a 119.52% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Apollomics Stock Performance

NASDAQ APLM opened at $23.92 on Wednesday. Apollomics Inc. has a 1 year low of $3.66 and a 1 year high of $42.12. The company has a fifty day moving average of $18.43 and a 200 day moving average of $17.34.

Institutional Trading of Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC purchased a new stake in shares of Apollomics Inc. (NASDAQ:APLM) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned 0.40% of Apollomics as of its most recent filing with the Securities & Exchange Commission. 19.13% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Apollomics currently has a consensus rating of “Sell”.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.